Skip to main content
72°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oric Pharmaceuticals Inc
(NQ:
ORIC
)
10.37
+0.17 (+1.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oric Pharmaceuticals Inc
< Previous
1
2
Next >
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
October 21, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
October 17, 2023
Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 06, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 01, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
August 30, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
June 26, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
May 08, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference
April 25, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 18, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
March 16, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting
March 14, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 06, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
February 01, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
January 09, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer
December 21, 2022
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting
December 13, 2022
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 08, 2022
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update
November 07, 2022
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022
From
ORIC Pharmaceuticals
Via
GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 07, 2022
From
ORIC Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.